FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **BevCanna Enterprises Inc.** (the "Issuer").

Trading Symbol: **BEV**

Number of Outstanding Listed Securities: 3,072,061

Date: March 4, 2024

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

- On February 8, 2024, the Company announced the results of its annual general meeting of shareholders held on February 6, 2024. The Company's shareholders approved all matters tabled at the annual general meeting, including the re-election of the Company's current board of directors: Marcello Leone; John Campbell; Martino Ciambrelli; and Howard Blank, and appointment of GreenGrowth CPAs Inc. as auditor of the Company. The Company's shareholders also approved the adoption of a new omnibus incentive plan in accordance with the requirements of the Canadian Securities Exchange (CSE), a share consolidation of up to 20:1, and approval to make application to the Supreme Court of British Columbia pursuant to Section 229 of the Business Corporations Act (British Columbia), for rectification of the Company's inability to hold an annual shareholders' meeting in 2022 and table audited financial statements at that time because of the prior Cease Trade Order.
- On February 16, 2024, the Company announced the intention to consolidate all of its issued and outstanding common shares (the "Common Shares") on the basis of 20:1, with each twenty (20) preconsolidated Common Shares being consolidated into one (1) post-consolidated Common Share (the "Consolidation"). The Company has approved a record date of February 26, 2024. As a result, management anticipates that the Common Shares will commence trading on the Canadian Securities Exchange on a post-consolidation basis at market open on Friday February 23, 2024. As required by CSE policies, the Company obtained shareholder approval for the Consolidation at the

Company's annual general and special meeting held on February 6, 2024. The proposed Consolidation has been approved by the Company's board of directors. Following the Consolidation, the Common Shares will begin trading on a consolidated basis under the existing Company name and trading symbol. The Consolidation would result in the number of issued and outstanding Common Shares being reduced from the current outstanding 61,441,210 Common Shares to approximately 3,072,061 Common Shares, subject to rounding. The board of directors of the Company believes the Consolidation will provide the Company with greater flexibility for future corporate activities, enhance the marketability of the Common Shares as an investment and lead to increased interest by a broader spectrum of potential investors, thereby increasing its ability to secure additional financing for operational and growth initiatives.

- On February 20, 2024, the Company announced that further to its news release dated February 14, 2024 announcing a proposed consolidation of its issued and outstanding common shares (each, a "Common Share") on the basis of twenty (20) pre-consolidation Common Shares for every one (1) post-consolidation Common Share (the "Share Consolidation"), the Company's new CUSIP number will be 08783B309 and its new ISIN number will be CA08783B3092 on the effective date of the Share Consolidation. As previously disclosed, and as a result of the Share Consolidation, the number of outstanding Common Shares will be reduced from 61,441,210 Common Shares to approximately 3,072,061 Common Shares, subject to adjustments for rounding. No fractional Common Shares will be issued as a result of the Share Consolidation. Where the exchange results in a fractional share, the number of Common Shares will be rounded up to the nearest whole Common Share. The exercise or conversion price and/or the number of Common Shares issuable with respect to any of the Company's outstanding convertible securities will be proportionately adjusted in connection with the Share Consolidation.
- On February 23, 2024, the Company announced that further to its previously disclosed news releases dated January 22, 2024 and January 29, 2024, its wholly-owned subsidiary, Naturo Group Enterprises Inc. ("Naturo") has closed the second tranche of its private placement financing (the "Note Offering") of secured promissory notes (each, a "Note") for gross proceeds of \$275,300. Each Note matures 12 months from the closing date and bears interest of 15% per annum, which interest was paid on closing and deducted from the gross proceeds of the Notes. The Notes are secured against all of Naturo's present and after-acquired personal property excluding Naturo's intellectual property. The Company intends to use the net proceeds from the Note

Offering for outstanding payables and general working capital purposes. No finder's fees were paid in connection with the closing of the second tranche of the Note Offering. The Company intends to close one or more additional tranches of the Note Offering.

- 2. Provide a general overview and discussion of the activities of management.
 - Manufacturing and fulfilling purchase orders for wellness and lifestyle consumer packaged goods portfolio.
 - Evaluating M&A opportunities.
- 3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
 - On February 23, 2024, the Company announced that further to its previously disclosed news releases dated January 22, 2024 and January 29, 2024, its wholly-owned subsidiary, Naturo Group Enterprises Inc. ("Naturo") has closed the second tranche of its private placement financing (the "Note Offering") of secured promissory notes (each, a

"Note") for gross proceeds of \$275,300. Each Note matures 12 months from the closing date and bears interest of 15% per annum, which interest was paid on closing and deducted from the gross proceeds of the Notes. The Notes are secured against all of Naturo's present and after-acquired personal property excluding Naturo's intellectual property. The Company intends to use the net proceeds from the Note Offering for outstanding payables and general working capital purposes. No finder's fees were paid in connection with the closing of the second tranche of the Note Offering. The Company intends to close one or more additional tranches of the Note Offering.

- 14. Provide details of any securities issued and options or warrants granted.
 - On February 23, 2024, the Company announced that further to its previously disclosed news releases dated January 22, 2024 and January 29, 2024, its wholly-owned subsidiary, Naturo Group Enterprises Inc. ("Naturo") has closed the second tranche of its private placement financing (the "Note Offering") of secured promissory notes (each, a "Note") for gross proceeds of \$275,300. Each Note matures 12 months from the closing date and bears interest of 15% per annum, which interest was paid on closing and deducted from the gross proceeds of the Notes. The Notes are secured against all of Naturo's present and after-acquired personal property excluding Naturo's intellectual property. The Company intends to use the net proceeds from the Note Offering for outstanding payables and general working capital purposes. No finder's fees were paid in connection with the closing of the second tranche of the Note Offering. The Company intends to close one or more additional tranches of the Note Offering.
- 15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The COVID-19 pandemic has resulted in the extended shutdown of certain businesses in various parts of the world, which may in turn result in disruptions or delays to our supply chain. These may include disruptions

from the temporary closure of third-party supplier and manufacturer facilities, interruptions in product supply or restrictions on the export or shipment of our products. Any disruption of our suppliers and their contract manufacturers may impact our sales and operating results. The outbreak of COVID-19 may also impact customer demand, the availability of key components that are sourced from other jurisdictions, logistics flows and the availability of other resources to support our operations.

To date the outbreak has not had a material adverse impact on our operations. However, the future impact of the outbreak is highly uncertain and cannot be predicted, and there is no assurance that the outbreak will not have a material adverse impact on the future results of the Issuer. The extent of the impact, if any, will depend on future developments, including actions taken to contain COVID-19.

FORM 7 - MONTHLY PROGRESS REPORT

Certificate Of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 4, 2024

Marcello Leone
Name of Director or Senior Officer
"Marcello Leone" Signature
CEO and Director Official Capacity

Issuer Details Name of Issuer BevCanna Enterprises Inc.	For Month End February 2024	Date of Report YY/MM/DD 24/03/04
Issuer Address PO Box 33957 Vancouver D CSC		
City/Province/Postal Code Vancouver, BC, V6J 4L7	Issuer Fax No. N/A	Issuer Telephone No. 604-569-1414
Contact Name Marcello Leone	Contact Position CEO and Director	Contact Telephone No. 604-569-1414
Contact Email Address info@bevcanna.com	Web Site Address	